Is aggressive treatment of smoldering myeloma the path to curing myeloma?
作者信息
Chakraborty Rajshekhar, Al Hadidi Samer, Cliff Edward R Scheffer, Mohyuddin Ghulam Rehman
机构信息
Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY.
Myeloma Section, Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences, Little Rock, AR.
出版信息
Blood Adv. 2023 Aug 8;7(15):3932-3935. doi: 10.1182/bloodadvances.2023009658.
Abstract
摘要
相似文献
1
Is aggressive treatment of smoldering myeloma the path to curing myeloma?
Blood Adv. 2023 Aug 8;7(15):3932-3935. doi: 10.1182/bloodadvances.2023009658.
2
How I approach smoldering multiple myeloma.
Blood. 2022 Aug 25;140(8):828-838. doi: 10.1182/blood.2021011670.
3
Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
J Natl Compr Canc Netw. 2020 Dec 1;18(12):1720-1729. doi: 10.6004/jnccn.2020.7660.
4
Progress in the Management of Smoldering Multiple Myeloma.
Curr Hematol Malig Rep. 2021 Apr;16(2):172-182. doi: 10.1007/s11899-021-00623-7. Epub 2021 May 13.
5
The consultant's guide to smoldering multiple myeloma.
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):551-559. doi: 10.1182/hematology.2022000355.
6
The Difficulty in Defining the True High-Risk Smoldering Myeloma.
Clin Cancer Res. 2024 Oct 1;30(19):4263-4265. doi: 10.1158/1078-0432.CCR-24-1382.
7
Smoldering multiple myeloma: biology, clinical manifestations and management.
Leuk Lymphoma. 2022 Mar;63(3):518-529. doi: 10.1080/10428194.2021.1992615. Epub 2021 Oct 21.
8
Smoldering multiple myeloma: Reviewing the rationale for intervention.
Leuk Lymphoma. 2022 Sep;63(9):2033-2040. doi: 10.1080/10428194.2022.2068008. Epub 2022 May 9.
9
Early Detection of Precursor Diseases of Multiple Myeloma.
Hematol Oncol Clin North Am. 2024 Aug;38(4):743-753. doi: 10.1016/j.hoc.2024.03.003. Epub 2024 May 9.
10
The difficult business of assessing new therapies for smouldering multiple myeloma.
Br J Haematol. 2018 Aug;182(4):463-464. doi: 10.1111/bjh.15385. Epub 2018 May 16.
引用本文的文献
1
Evaluating early intervention in smoldering myeloma clinical trials: a systematic review.
Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyae219.
2
Is It Possible to Predict Tumor Progression Through Genomic Characterization of Monoclonal Gammopathy and Smoldering Multiple Myeloma?
Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024044. doi: 10.4084/MJHID.2024.044. eCollection 2024.
3
Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey.
EClinicalMedicine. 2023 Oct 24;65:102272. doi: 10.1016/j.eclinm.2023.102272. eCollection 2023 Nov.
4
Determination of the target of monoclonal immunoglobulins: a novel diagnostic tool for individualized MGUS therapy, and prevention and therapy of smoldering and multiple myeloma.
Front Immunol. 2023 Oct 31;14:1253363. doi: 10.3389/fimmu.2023.1253363. eCollection 2023.
本文引用的文献
1
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
Lancet Haematol. 2023 Mar;10(3):e203-e212. doi: 10.1016/S2352-3026(22)00386-6.
2
Prevalence of smoldering multiple myeloma based on nationwide screening.
Nat Med. 2023 Feb;29(2):467-472. doi: 10.1038/s41591-022-02183-6. Epub 2023 Feb 6.
3
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14.
4
Survival in smouldering myeloma and symptomatic myeloma: Is there an emerging Will Rogers phenomenon?
Eur J Cancer. 2022 Sep;172:234-236. doi: 10.1016/j.ejca.2022.05.041. Epub 2022 Jul 4.
5
Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage.
Br J Haematol. 2022 Oct;199(1):65-75. doi: 10.1111/bjh.18232. Epub 2022 May 24.
6
How I approach smoldering multiple myeloma.
Blood. 2022 Aug 25;140(8):828-838. doi: 10.1182/blood.2021011670.
7
Financial toxicity in hematological malignancies: a systematic review.
Blood Cancer J. 2022 Apr 22;12(4):74. doi: 10.1038/s41408-022-00671-z.
8
The Time Toxicity of Cancer Treatment.
J Clin Oncol. 2022 May 20;40(15):1611-1615. doi: 10.1200/JCO.21.02810. Epub 2022 Mar 2.
9
Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials.
Br J Haematol. 2022 Jun;197(6):e86-e88. doi: 10.1111/bjh.18102. Epub 2022 Feb 28.
10
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis.
Blood Cancer J. 2021 Nov 26;11(11):186. doi: 10.1038/s41408-021-00569-2.
Zotero 插件